Literature DB >> 22275389

Long-term outcomes in acute pulmonary thromboembolism: the incidence of chronic thromboembolic pulmonary hypertension and associated risk factors.

Ahmet Korkmaz1, Tevfik Ozlu, Savas Ozsu, Zeynep Kazaz, Yilmaz Bulbul.   

Abstract

The long-term outcomes of pulmonary thromboembolism (PTE) and/or incidence of chronic thromboembolic pulmonary hypertension (CTEPH) are not well documented. Three hundred twenty-five consecutive cases objectively diagnosed with PTE monitored for an average 16.3 months (6-50.7 months) were investigated. Data concerning recurrence, residual thrombus, mortality, and CTEPH in particular were collected. Chronic thromboembolic pulmonary hypertension frequency acute first episode of PTE was 4.6%. Chronic thromboembolic pulmonary hypertension developed within 12 months after PTE attack in approximately 80% of patients and it did not occur after 2 years. Residual chronic thrombus was determined at the 3rd month in 48% of cases post-PTE, at the 6th month in 27.4%, and at the 12th month in 18.2%. At multivariate regression analysis, systolic pulmonary arterial pressure > 50 mm Hg, hazard ratio: 10.1 (95% confidence interval: 4.1-71.2) were predictors of CTEPH. Chronic thromboembolic pulmonary hypertension develops as a serious complication in a significant number of cases with PTE. Closer monitoring of high-risk cases in particular is important in terms of early diagnosis and treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22275389     DOI: 10.1177/1076029611431956

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  25 in total

Review 1.  Classification and diagnosis of pulmonary hypertension.

Authors:  Hector R Cajigas; Rana Awdish
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  The Incidence and Related Risk Factors of Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism.

Authors:  Halil Tosun; Gamze Kırkıl; Figen Deveci; Necati Dağlı; Mete Özcan; Selda Telo
Journal:  Turk Thorac J       Date:  2016-04-01

Review 3.  Imaging of Chronic Thromboembolic Disease.

Authors:  Adina Haramati; Linda B Haramati
Journal:  Lung       Date:  2020-03-12       Impact factor: 2.584

4.  Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism.

Authors:  Suqiao Yang; Yuanhua Yang; Zhenguo Zhai; Tuguang Kuang; Juanni Gong; Shuai Zhang; Jianguo Zhu; Lirong Liang; Ying H Shen; Chen Wang
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

Review 5.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 6.  Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.

Authors:  David S Poch; William R Auger
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

7.  Hypoxia-inducible factor 1 alpha contributes to pulmonary vascular dysfunction in lung ischemia-reperfusion injury.

Authors:  Xin Zhao; Yanwu Jin; Haibo Li; Zhigang Wang; Wanlin Zhang; Chang Feng
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

Review 8.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

Review 9.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

10.  Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies.

Authors:  Meng Zhang; Ning Wang; Zhenguo Zhai; Mingyuan Zhang; Rongrong Zhou; Yanyan Liu; Yuanhua Yang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.